Marken Announces the Expansion of their Clinical Supply Depot Network
As part of its continued expansion of services in Latin America, Marken has announced the planned September 1, 2011 launch of their Latin America regional depot network with facilities in Mexico City and Buenos Aires.
Marken is executing on its stated plan to build the most advanced, fit for purpose, pharmaceutical-focused clinical distribution network. This expanded network allows the company to build from its current industry-leading life sciences logistics platform, which serves over 6,000 investigator sites in 100 countries from its 24 global branch offices.
The Singapore facility is fully operational and has been successfully audited by several client companies. Additional depot facilities are planned in the Middle East, Europe, Asia and the Americas. This global network of direct-controlled, GMP-compliant depots allows maximum efficiency in the conduct of clinical trials, even in clinically-naïve regions.
“The expansion of these facilities is just one more step in supporting our clients’ needs in controlling the chain-of-custody of clinical trial assets.” said Wes Wheeler, Marken’s Chief Executive Officer. “Our goal is to be the premier provider of life sciences supply chain services. We are 100% focused on life sciences and will ensure that the strict requirements unique to the pharmaceutical and medical device communities are met, particularly with the recent focus on new regulatory documentation, strict temperature control and chain of custody.”
Each of Marken’s depots will also offer specimen kit distribution, collection, storage and management; and reverse logistics for dosage kits, drugs and equipment, including reconciliation and certified destruction. The Mexico and Argentina storage facilities include the full range of temperature control including controlled ambient, cold storage (2º-8ºC) and frozen (-20ºC) as well as secured drug store.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
